Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U-PRIMED Study (Upper Tract Urothelial Carcinoma – Perioperative Real-world Investigation)
jRCT1051250191Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cisplatin and carboplatin in upper tract urothelial carcinoma (UTUC), renal pelvis cancer and ureteral cancer (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Disease-free survival. Started Jan 2026; status: active, not recruiting.
02
Drugs
cisplatincarboplatin
03
Conditions
upper tract urothelial carcinoma (UTUC)renal pelvis cancerureteral cancer
Beyond the preview
Go deeper on jRCT1051250191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051250191.